AVDL.O Hits 52-Week High Amid Acquisition Buzz

Shares of Avadel Pharmaceuticals (AVDL.O) surged to a 52-week high today, climbing approximately 19% to $22.50 in pre-market trading. This significant price movement follows an unsolicited acquisition proposal from Danish drugmaker Lundbeck, which offers up to $23 per share, surpassing a previous bid from Alkermes. The heightened investor interest is fueled by the competitive nature of the bids, as Lundbeck's offer includes $21 in cash and potential additional payments tied to sales performance of Avadel's products. Meanwhile, ongoing investigations into the company by Halper Sadeh LLC for potential securities violations add a layer of complexity to the situation, prompting shareholders to consider their legal rights. As the market reacts to these developments, Avadel's board continues to evaluate the merits of both offers.